Back to top

Image: Bigstock

Cannabis Stock CGC Loses 26% in a Month: Should You Buy the Dip?

Read MoreHide Full Article

Key Takeaways

  • Canopy Growth shares fell more than 25% after fiscal second-quarter earnings and sales missed estimates.
  • International cannabis revenues rose 58% to C$21.9 million, driven by stronger sales in Germany and Poland.
  • Margin pressures, persistent losses and widening estimates raise concerns about CGC's path to profitability.

Shares of Canopy Growth Corporation (CGC - Free Report) have lost more than a quarter of their market value in the past month, attributable to the company's latest quarterly results weighing on investor sentiment.

Earlier this month, CGC reported second-quarter results for fiscal 2027 (year ending March 2027) that missed our consensus estimates for both earnings and sales. While the revenue shortfall was relatively modest, the bottom-line miss was more significant, raising concerns about the company's progress toward profitability.

However, the results also highlighted encouraging growth across Canopy's cannabis business, particularly in international markets, along with continued progress in cost management. At the same time, margin pressures and persistent losses remain concerns. Let's take a closer look at the company's fundamentals to assess whether the recent decline presents a buying opportunity.

CGC's Revenues Continue to Grow But Margins Under Pressure

Canopy Growth continues to report encouraging growth, supported by its international medical cannabis operations and contributions from Canada. During the first half of fiscal 2027, consolidated net revenues increased 17% year over year to C$162.5 million, reflecting improved flower availability, a broader product portfolio and the integration of MTL Cannabis. The MTL acquisition, which was completed in March 2026, added cultivation expertise, patient networks and production capacity.

Canadian cannabis operations delivered double-digit growth during the first half, supported by MTL's contribution and improved product availability. However, medical cannabis sales continue to face pressure from lower Veterans Affairs Canada (“VAC”) reimbursement rates, partly offsetting patient additions. MTL brands have performed well in the adult-use market, particularly in Quebec, while Canopy is strengthening its domestic sales efforts.

International cannabis operations remain the strongest growth driver, with revenues increasing 58% year over year to C$21.9 million in first-half 2027. Growth was primarily driven by stronger medical cannabis sales in Germany and Poland, supported by improved flower availability and expanded distribution. Canopy has also strengthened its German commercial team, entered the U.K. medical cannabis market and broadened its Australian product portfolio.

Storz & Bickel (S&B), Canopy's vaporization business, reported a modest 1% revenue increase to C$31.2 million during the first half, as growth in some markets was offset by weaker consumer spending elsewhere. Management continues to refine its product portfolio and go-to-market strategy and expects holiday demand to support third-quarter sales.

Margins, however, remain under pressure. Adjusted gross margin declined to 31% in the second quarter of fiscal 2027 from 33% a year ago, primarily due to lower VAC reimbursement rates, partially offset by improvements in its S&B business. Still, Canopy's adjusted EBITDA loss narrowed to C$2.9 million, an improvement of C$0.2 million year over year, supported by revenue growth and cost savings.

Looking ahead, management remains on track to achieve positive adjusted EBITDA during the second half of fiscal 2027, supported by seasonal strength at S&B, cost controls and MTL integration synergies. Further out, cultivation improvements at the Kincardine facility are expected to increase flower production by 25-30% within the existing footprint, with fuller benefits anticipated in fiscal 2028. These initiatives, along with Canopy's strengthened European supply chain, could support further revenue growth and margin improvement.

Cutthroat Competition in Targeted Markets

Canopy Growth competes in an overcrowded market against the likes of Tilray Brands (TLRY - Free Report) and Village Farms International (VFF - Free Report) . Both companies are expanding their international cannabis operations, particularly in Europe, intensifying competition for medical cannabis demand in key markets such as Germany.

Tilray Brands is also strengthening its international medical cannabis operations through Tilray Medical and its pharmaceutical distribution business, CC Pharma. Earlier this year, Tilray also acquired HelloMD, a digital healthcare and patient engagement platform, to strengthen patient access and expand its direct-to-patient capabilities in Canada.

Village Farms International has been expanding its medical cannabis exports, with Europe, particularly Germany, emerging as an important growth market. The company continues to hold a leading position in Germany and is expanding its production capacity in the Netherlands to support further international growth.

CGC Stock Performance & Estimates

Year to date, shares of Canopy Growth have plummeted more than 53% compared with the industry’s nearly 16% decline.

Zacks Investment Research
Image Source: Zacks Investment Research

Loss estimates for fiscal 2027 and 2028 have widened in the past 30 days.

Zacks Investment Research
Image Source: Zacks Investment Research

How to Play CGC Stock?

While Canopy Growth continues to report encouraging revenue growth, the sustainability of its international expansion remains uncertain, particularly amid increasing competition in Germany and the need to maintain consistent product supply. Moreover, the company still needs to demonstrate that its operational improvements can translate into sustainable profitability. Analyst sentiment has also weakened, with loss estimates for fiscal 2027 and 2028 widening over the past 30 days.

Given these concerns, investors may be better off selling their existing positions rather than holding on to the stock in anticipation of a recovery. The stock currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in